文献速递妇科

现代盆腔廓清术经验:与非卵巢妇科恶性肿瘤相关的手术结局

A modern-day experience with Brunschwig's operation: Outcomes associated with pelvic exenteration.
PubMed 文献 · Gynecol Oncol · 2022-09-03

该回顾性研究纳入2010年1月1日至2019年12月31日在本机构因非卵巢妇科恶性肿瘤接受盆腔廓清术的100例患者,评估术后及肿瘤学结局。结果显示围术期并发症发生率高达97%,但无术中或术后30天内死亡;3年无进展生存率为61.0%,3年总生存率为61.6%。

要点

  • 100例患者中97例发生围术期并发症,50例发生重大并发症(Grade ≥3)。
  • 无术中或术后30天内死亡,6例在术后30天后死亡。
  • 3年无进展生存率61.0%,3年总生存率61.6%;58例存活者中16例(28%)存活超过5年,4例(7%)超过10年。

核心结论

  • 盆腔廓清术的总体并发症率仍然很高,因发生率接近100%,未发现与并发症发生相关的变量。
  • 围术期死亡率低,可能归因于围术期护理的改善。

研究设计与样本

  • 回顾性综述,纳入2010年1月1日至2019年12月31日在本机构因非卵巢妇科恶性肿瘤接受盆腔廓清术的患者。
  • 共识别100例患者:89例因复发疾病手术,5例为姑息性手术,5例为原发疾病,1例为持续性疾病。
  • 姑息性廓清术病例从生存分析中排除。
  • 术后并发症分为早期(≤30天)或晚期(31-180天),使用经过验证的机构量表分级,重大并发症定义为Grade ≥3。
  • 分类变量采用卡方检验,生存分析采用Kaplan-Meier法。

主要发现

  • 30%为宫颈癌,27%为外阴癌,24%为子宫癌,19%为阴道癌。
  • 62%接受全盆腔廓清术,30%接受前盆腔廓清术,8%接受后盆腔廓清术。
  • 无术中或术后30天内死亡,6例在术后30天后死亡。
  • 97例发生围术期并发症:49例仅早期,1例仅晚期,47例早期和晚期均有。
  • 50例发生重大并发症:22例(44%)仅早期,19例(38%)仅晚期,9例(18%)早期和晚期均有。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate postoperative and oncologic outcomes associated with pelvic exenteration for non-ovarian gynecologic malignancies. METHODS: This was a retrospective review of patients who underwent pelvic exenteration for non-ovarian gynecologic malignancies at our institution from 1/1/2010-12/31/2019. Palliative exenteration cases were excluded from survival analysis. Postoperative complications were early (≤30 days) or late (31-180 days). Complications were graded using a validated institutional scale. Major complications were considered grade ≥ 3. Categorical variables were compared using the chi-square test, and the Kaplan-Meier method was used for survival analysis. RESULTS: Of 100 patients identified, 89 underwent pelvic exenteration for recurrent disease, 5 for palliation, 5 for primary disease, and 1 for persistent disease. Thirty percent had cervical, 27% vulvar, 24% uterine, and 19% vaginal cancer. Sixty-two percent underwent total, 30% anterior, and 8% posterior exenteration. No deaths occurred intraoperatively or within 30 days of surgery. Six patients died after 30 days. Ninety-seven experienced a perioperative complication-49 early, 1 late, and 47 both. Fifty experienced a major complication-22 (44%) early, 19 (38%) late, and 9 (18%) both. No variables were statistically associated with complication development. The 3-year progression-free survival rate was 61.0%; the 3-year overall survival rate was 61.6%. Of 58 surviving patients, 16 (28%) and 4 (7%) were alive after 5 and 10 years, respectively. CONCLUSION: The overall complication rate for pelvic exenteration remains high. No variables demonstrated association with complication development as the rate was nearly 100%. The low rate of perioperative mortality is likely due to improved perioperative care.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rios-Doria E, Filippova OT, Straubhar AM, et al. A modern-day experience with Brunschwig's operation: Outcomes associated with pelvic exenteration. Gynecol Oncol. 2022. PMID: 36064678. doi:10.1016/j.ygyno.2022.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。